Stand 16.08.2019

Publications

Original work in peer-reviewed journals

(1) Chakievska L, Holtsche MM, Künstner A, Goletz S, Petersen BS, Thaci D, Ibrahim SM, Ludwig RJ, Franke A, Sadik CD, Zillikens D, Hölscher C, Busch H, **Schmidt E**. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 2019; 96: 104-12. IF 7.6

(2) Goletz S, Probst C, Komorowski L, Schlumberger W, Fechner K, van Beek N, Holtsche MM, Recke A, Yancey KB, Hashimoto T, Antonicelli F, Di Zenzo G, Zillikens D, Stöcker W, **Schmidt E**. Sensitive and specific assay for the serological diagnosis of anti-laminin 332 mucous membrane pemphigoid. Br J Dermatol 2019, 180: 149-56. IF 6.1

(3) Lau I, Goletz S, Holtsche, MM, Zillikens D, Fechner K, **Schmidt E**. Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. J Am Acad Dermatol 2019, in press. IF 6.9

(4) Egu DT, Sigmund AM, **Schmidt E**, Spindler V, Walter E, Waschke J. p38MAPK inhibition is not effective to prevent autoantibody-induced mucosal blistering in pemphigus. Br J Dermatol 2019, in press. IF 6.1

(5) Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, **Schmidt E**, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight 2019, 8:4. IF 6.0

(6) Mahmoudi H, Toosi R, Kamyab K, Zillikens D, **Schmidt E**, Daneshpazhooh M. Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LAD-1). J Dtsch Dermatol Ges 2019, in press. IF 2.7

(7) Wald A, **Schmidt E**, Toberer F, Enk AH, Hoffmann J. Overlap of bullous, anti-laminin 332 and p200 pemphigoid with concomitant anti-contactin 1-positive inflammatory polyneuropathy treated with intravenous immunoglobulins as a manifestation of epitope spreading. JAMA Dermatol 2019, in press. IF 8.1

(8) Gutjahr A, Heck F, Emtenani S, Hammers AK, Hundt J, Muck P, Siegel DL, **Schmidt E**, Stanley JR, Zillikens D, Hammers CM. Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium. Br J Dermatol 2019, in press; IF 6.1

(9) Shi C, Meijer J, Guoc J, Azzopardia G, Diercks G, **Schmidt E**, Zillikens D, Jonkman MF, Petkova N. Detection of *u*-serrated patterns in direct immunofluorescence images of autoimmune bullous diseases by inhibition-augmented COSFIRE filters. Int J Med Inform 2019, 122: 122-27. IF 3.0

(10) Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, **Schmidt E**, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French. Large international validation of ABSIS and PDAI pemphigus severity scores. J Invest Dermatol 2019,139: 31-37, IF 6.4

(11) Daneshpazhooh M, Mahmoudi H, Toosi R, Tavakolpour S, **Schmidt E**, Zillikens D. Post-orf epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 2019, 33:118-19. IF 4.3

(12) Syring FM, Zillikens D, **Schmidt E**, KasperkiewiczM. Anti-Laminin 332 Schleimhautpemphigoid mit irreversiblem okulären und tracheobronchialen Befall. Hautarzt 2019, in press. IF 0.6

(13) Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze F, Heppe EN, Ludwig R, Zillikens D, König IR, Köhl J, **Schmidt E**. Tissue destruction in bullous pemphigoid can be complement-independent and may be mitigated by C5aR2. Front Immunol 2018, 9: 488. IF 4.7

(14) Holtsche MM Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman Levell ANJ, Groves R, Williams HV, König IR, **Schmidt E**. Prospective study in bullous pemphigoid: Association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. Br J Dermatol 2018, 179: 918-24. IF 6.7

(15) Hofrichter M, Dworschak J, Langenhan J, Weiß F, Komorowski L, Zillikens D, Stöcker W, Probst C, **Schmidt E***, Goletz S*. Immunoadsorption of anti-desmoglein 3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. Front Immunol 2018, 9: 1935. *equal contribution, IF 4.7

(16) Spindler V*, Eming R*, **Schmidt E***, Amagai M, Grando S, Jonkman MF, Kowalczy AP, Müller EJ, Payne AS, Pincelli C, Sinha AA, Sprecher E, Zillikens D*, Hertl M*, Waschke J*. Mechanisms causing loss of keratinocyte cohesion in pemphigus. J Invest Dermatol 2018, 138: 32-37. *equal contribution, IF 6.3

(17) Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, Benoit S, El-Chennawy F, Eldarouti M, Eming R, Gläser R, Günther C, Hadaschik E, Homey B, Lieb W, Peitsch WK, Pföhler C, Robati RM, Saeedi M, Sárdy M, Sticherling M, Uzun S, Worm M, Zillikens D, Ibrahim S, Vidarsson G, **Schmidt E**, and the German AIBD Genetic Study Group. The p.Arg435His variation of IgG3 with high affinity to FcRn is associated with susceptibility for pemphigus vulgaris – analysis of four different ethnic cohorts. Front Immunol 2018, 9: 1788. IF 4.7

(18) Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Süfke S, Muck P, Zillikens D, **Schmidt E**. Adjuvant tratment of severe/ refractory bullous pemphigoid with protein A immunoadsorption leads to rapid diseases control and decrease of anti-BP180 autoantibody levels. J Dtsch Dermatol Ges 2018, 16: 1109-18. IF 3.9

(19) Kasperkiewicz M, Mook SC, Knuth-Rehr D, Vorobyev A, Ludwig R, Zillikens D, Muck P, **Schmidt E**. IgE-selective immunoadsorption for severe atopic dermatitis. Front Med 2018, 5: 27. IF 3.1

(20) Hügel R, Lang A, Lhotta K, Elsässer W, Gächter W, Messmer EM, **Schmidt E**. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoadsorption and rituximab. J Dtsch Dermatol Ges 2018, 16: 897-900. IF 3.9

(21) Haeberle S, Wei X, Bieber K, Goletz S, Ludwig RJ, **Schmidt E**, Enk AH, Hadaschik EN. Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. J Allergy Clin Immunol 2018, 142: 1831-42. IF 14.1

(22) Meijer JM, Atefi I, Diercks G, Vorobyev A, Zuiderveen J, Meijer JH, Pas HH, Zillikens D, **Schmidt E**, Jonkman M. Serration pattern analysis for differentiating epidermolysis bullosa acquisita from pemphigoid variants. J Am Acad Dermatol 2018, 78: 754-759. IF 7.1

(23) Prost-Squarcioni C, Caux F, **Schmidt E**, Jonkman MF, Vassileva S, Kim SC, Iranzo P, Daneshpazhooh M, Terra J, Bauer J, Fairley J, Hall R, Hertl M, Lehman JS, Marinovic B, Patsatsi A, Zillikens D, Werth V, Woodley DT, Murrell DF. Internationa Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol 2018, 179: 30-14 IF 6.7

(24) Murrell D, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne A, Daneshpazhooh M, Eming R,Jonkman M, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman J, Saleh MA, Culton D, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakas A, Bernard P, Korman N, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman R, Cardones A, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, **Schmidt E**, Aoki V, Grando S, Shimizu H, Baum S, Cianchini G, Feliciani C,Iranzo P Mascar J, Kowalewski C, Hall R, Groves R, Harman K, Marinkovich P, Maverakis E, Werth V. Diagnosis and management of pemphigus: Recommendations by an international panel of experts. J Am Acad Dermatol 2018, in press. IF 7.1

(25) Hübner F, Setterfield J, Recke A, Zillikens D, **Schmidt E**, Dart J, Ibrahim S. HLA alleles in British Caucasians with mucous membrane pemphigoid. Eye 2018, 32: 1540-41. IF 2.4

(26) Emtenani S, Yuan H, Lin C, Pan M, Hundt JE, **Schmidt E**, Komorowski L, Stanley JR, Hammers CM. Normal human skin is superior to monkey esophagus substrate for detection of circulating BP180-NC16A-specific immunoglobulin G antibodies in bullous pemphigoid. Br J Dermatol 2018, in press, IF 6.7

(27) Menzinger S, Kaya G, **Schmidt E**, Fontao L, Laffitte E. Biological and clinical response to omalizumab in a patient with bullous pemphigoid. Acta Derm Venereol 2018, 98: 284-86. IF 3.5

(28) Kasprick A, Holtsche M, Kauderer C, **Schmidt E**, Petersen F, Panicker S, Ludwig R. The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. J Invest Dermatol 2018, 138: 458-61. IF 6.3

(29) Tukaj S, Bieber K, Witte M, Ghorbanalipoor S, **Schmidt E**, Zillikens D, Ludwig R, Kasperkiewicz M. Calcitriol treatment ameliorates inflammation and blistering in mouse models of epidermolysis bullosa acquisita. J Invest Dermatol 2018, 138: 301-309. IF 6.3

(30) Samavedam U, Mitschker N, Kasprick A, Bieber K, **Schmidt E**, Laskay T, Recke A, Vidarsson G, Schulze FS, Armbrust M, Schulze Dieckhoff K, Pas HH, Jonkman M, Kalies K, Zillikens D, Gupta Y, Ibrahim S, Ludwig R. Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita. Front Immunol 2018, 9: 249. IF 4.7

(31) Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, **Schmidt E**, Harman K, Walton S, Chapman A, Williams HC; U.K.Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. Br J Dermatol 2018, 178: 415-23. IF 6.7

(32) Jankásková J, Horváth ON, Varga R, Arenberger P, **Schmidt E**, Ruzicka T, Sárdy M. Increased sensitivity along with high specificity of indirect immunofluorescence detecting IgG subclasses for diagnosis of bullous pemphigoid. Clin Exp Dermatol 2018, 43: 248-53. IF 1.7

(33) Ellenbogen E, Geller S, Azrielant S, Zeeli T, Goldberg I, **Schmidt E**, Zillikens D, Sherman S, Mercer S, Didkovsky E, Hodak E, Sprecher E.Grover disease and bullous pemphigoid: a clinicopathologic study of six cases. Clin Exp Dermatol 2018, in press. IF 1.7

(34) Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, **Schmidt E**, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T. Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy: Data from a nationwide German registry (GRAID2). Z Rheumatol 2018, 77: 28-39. IF 0.9

(35) **Schmidt E**. Rituximab as first line therapy of pemphigus (translational comment). Lancet 2017, 389: 1956-58. IF 53.2

(36) Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C, Zillikens D, Köhl J, Goletz S, **Schmidt E**. Experimental laminin 332 mucous membrane pemphigoid reflects clinical and immunopathological characteristics of the human disease and critically involves C5aR1. J Invest Dermatol 2017, 137: 1709-18. IF 6.4

(37) van Beek N, Lütmann N, Hübner F, Recke A, Karl I, Schulze FS, Zillikens D, **Schmidt E**. Serum levels of IgE autoantibodies against BP180: correlation with disease activity in patients with bullous pemphigoid but not with the type of clinical presentation. JAMA Dermatol 2017, 153: 30-38. IF 8.1

(38) van Beek N, Dähnrich C, Johannsen N, Lemcke S, Goletz S, Hübner F, Di Zenzo G, Dmochowski M, Drenovska K, Geller S, Horn M, Kowalewski C, Medenica L, Murrell DF, Patsatsi A, Uzun S, Vassileva S, Zillikens D, Schlumberger W, **Schmidt E**. Prospective studies on the routine use of a novel multivariant ELISA for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol 2017, 76: 889-894. IF 6.9

(39) Sticherling M, Franke A, Aberer E, Gläser R, Hertl M, Pfeiffer C, Rzany B, Schneider S, Shimanovich I, Werfel T, Wilczek A, Zillikens D, **Schmidt E**. An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone

and azathioprine with methylprednisolone and dapsone. Br J Dermatol 2017; 177: 1299-1305. IF 6.1

(40) Sadik C, Pas HH, Bohlmann MK, Mousavi S, Benoit S, Sárdy M, Terra JB, Lima AL,. Hammers CM, van Beek N, Bangert C, Zillikens D, **Schmidt E**. Value of BIOCHIP technology in the diagnosis of pemphigoid gestationis. Acta Dermatol Venereol (Stockh.) 2017, 97: 128-30. IF 3.1

(41) Mindorf S, Dettmann I, Krüger S, Fuhrmann T, Rentzsch K, Ingolf K, Probst C, Komorowski L, Fechner K, van Beek N, Lemcke S, Sárdy M, Bangert C, Benoit S, Hashimoto T, Zillikens D, Pas H, Jonkman M, Stöcker W, **Schmidt E**. Routine detection of serum anti-desmocollin autoantibodies is only useful in patients with atypical pemphigus. Exp Dermatol 2017, 26: 1267-70. IF 2.6

(42) **Schmidt E**, Spindler V, Eming R, Amagai M, Antonicelli F, Baines JF, Belheouane M, Bernard P, Borradori L, Caproni M, Di Zenzo G, Grando S, Harman K, Jonkman MF, Koga H, Ludwig R, Kowalczyk AP, Müller EJ, Nishie W, Pas H, Payne A, Sadik C, Seppänen A, Setterfield J, Shimizu H, Sinha AA, Sprecher E, Sticherling M, Ujiie H, Zillikens D, Hertl M, Waschke J. Meeting report of the *Pathogenesis of Pemphigus and Pemphigoid Meeting* in Munich, September 2016. J Invest Dermatol 2017, 137: 1199-1203. IF 6.4

(43) **Schmidt E**, Benoit S, Kampik D, Hille K, Geerling G. Tibia-keratoprosthesis: Reversing blindness in mucous membrane pemphigoid. J Dtsch Dermatol Ges 2017, 15: 1024-26. IF 2.7

(44) Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, **Schmidt E**, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid – a pragmatic non-inferiority randomised controlled trial. Lancet 2017, 389: 1630-38. IF 53.2

(45) Williams HC, Chalmers JR, Nunn AJ, **Schmidt E**. BLISTER tests the strategy of starting pemphigoid treatment with doxycycline (reply). Lancet 2017, 390: 135-36. IF 53.2

(46) Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, **Schmidt E**, Godec TR, Nunn AJ, Williams HC. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Health Technol Asses 2017, 21: 1-90. IF 4.2

(47) Miodovnik M, Künstner A, Langan E, Zillikens D, Gläser R, Sprecher E, Baines J*, **Schmidt E***, Ibrahim S*. A distinct cutaneous microbiota profile in autoimmune bullous diseases patients. Exp Dermatol 2017, 26: 1221-27. IF 2.6. * equal contribution

(48) Sezin T, Krajewski M, Wutkowski A, Mousavi S, Bieber K, Ludwig R, Dahlke M, Rades D, Schulze FS, **Schmidt E**, Kalies K, Gupta Y, Schilf P, Ibrahim S, König P, Schwudke D, Zillikens D, Sadik C. The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. J Invest Dermatol 2017, 137: 1104-13. IF 6.4

(49) Bieber K, Sun S, Witte M, Kasprick A, Beltsiou F, Behnen M, Laskay T, Schulze FS, Pipi E, Reichhelm N, Pagel R, Zillikens D, **Schmidt E**, Sparwasser T, Kalies K, Ludwig R. Regulatory T cells suppress inflammation and blistering in pemphigoid diseases. Front Immunol 2017, 8: 1628. IF 5.5

(50) Bieber K, Ernst AL, Tukaj S, Holtsche M, **Schmidt E**, Zillikens D, Ludwig R, Kasperkiewicz M. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Exp Dermatol 2017, 26: 1248-52. IF 2.6

(51) Sadik C, Bischof J, van Beek N, Dieterich A, Benoit S, Sardy M, Worm M, Meller S, Gläser R, Zillikens D, Homey B, Setterfield J, Minassian D, **Schmidt E**, Dart J, Ibrahim S. Genome-wide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid. Exp Dermatol 2017, 26: 1214-20. IF 2.6

(52) Maier L, Udvardi A, Hertl M, Eming R, **Schmidt E**, Zillikens D, Volc-Platzer B. Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman's disease. Br J Dermatol 2017, 176: 824-26. IF 6.1

(53) Walter E, Vielmuth F, Rotkopf L, Sardy M, Horváth ON, Goebeler M, **Schmidt E**, Eming R, Hertl M, Spindler V, Waschke J. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. Sci Rep 2017, 7: 3579. IF 4.1

(54) Bağcı IS, Horváth ON, **Schmidt E**, Ruzicka T, Sárdy M. Diagnostic Value of linear fluorescence along the basement membrane of sweat gland ducts in bullous pemphigoid. Acta Derm Venereol 2017, 97: 622-26. IF 3.1

(55) Reichel A, Benoit S, Giner T, **Schmidt E**, Goebeler M, Stoevesandt J. Anti-desmoglein 1 IgG/IgA pemphigus associated with thymoma. J Dtsch Dermatol Ges 2017, 15: 1147-49. IF 2.7

(56) Mergler R, Kerstan A, **Schmidt E**, Goebeler M, Benoit S. Atypical clinical and serological manifestation of pemphigus vegetans: A case report and review of the literature. Case Rep Dermatol 2017, 9: 121-30. IF 0.25

(57) Patsatsi A, Parthena M, Katafygiotis S, Sotiriadis D, **Schmidt E**, Lambropoulos A. Chronic bullous disease of childhood with IgG reactivity to p200 antigen. Int J Dermatol 2017, 56: 773-75. IF 1.5

(58) Goyal N, Rao R, Shenoi SD, Pai S, Kumar P, Bhogal BS, **Schmidt E**, Zillikens D. Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin. Indian J Dermatol Venereol Leprol 2017, 83: 550-55. IF 2.2

(59) Hirose M, Kasprick A, Beltisou F, Schulze-Dieckhoff K, Schulze FS, Samavedam U, Hundt J, Pas H, Jonkman M, **Schmidt E**, Kalies K, Zillikens D, Ludwig R, Bieber K. Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment. Mol Med 2016, 22: 918-26. IF 3.5

(60) Hübner F, Recke A, Zillikens D, Linder R, **Schmidt E**. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 2016, 136: 2495-98. IF 6.3

(61) Recke A, Oei A, Hübner F, Fechner K, Graf J, Hagenah J, May C, Woitalla D, Salmen A, Zillikens D, Gold R, Schlumberger W, **Schmidt E**. Parkinson's disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. Br J Dermatol 2016, 175: 407-09. IF 4.7

(62) **Schmidt E**. Increasing the diagnostic sensitivity for mucous membrane pemphigoid by detection of salivary autoantibodies (commentary). Br J Dermatol 2016, 174: 956-57. IF 4.7

(63) Mersmann M, Dworschak J, Ebermann K, Komorowsk L, Schlumberger W, Stöcker W, Zillikens D, Probst C, **Schmidt E**. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res 2016, 308: 31-38. IF 2.3

(64) Lemcke S, Sokolowski S, Rieckhoff N, Buschtez M, Kaffka C, Winter-Keil A, Schaller C, Rottmann N, Sadik C, Stöcker W, Zillikens D, **Schmidt E**. Automation of direct immunofluorescence microscopy for skin biopsies to improve accuracy and efficiency in routine diagnostics. J Cutan Pathol 2016, 43: 227-35. IF 1.4

(65) Commin MH, **Schmidt E**, Duvert-Lehembre S, Lasek A, Morice C, Estival JL, Debarbieux S, Rigal E, Pauwels C, De Quatrebarbes J, Roussel A, Goujon E, Stoebner PE, Jouen F, Joly P. Clinical and immunological features and outcome of anti-p200 pemphigoid. Br J Dermatol 2016, 175: 776-81. IF 4.7

(66) Meijer JM, Diercks G, **Schmidt E**, Pas H, Jonkman MF. Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol 2016, 152:897-904. IF 5.8

(67) Ahmed R, Carrozzo M, Caux F, Cirillo N, Dmochowski M, Alonso A, Gniadecki R, Hertl M, López-Zabalza M, Lotti R, Pincelli C, Pittelkow M, **Schmidt E**, Sinha A, Sprecher E, Grando S. Monopathogenic versus multipathogenic explanations of pemphigus pathophysiology. Exp Dermatol 2016, 72: 168-74. IF 3.8

(68) Geller S, Gat A, Zeeli T, **Schmidt E**, Ishii N, Hashimoto T, Zillikens D, Sprecher E. A refractory, cutaneous, subepidermal bullous disease. Clin Exp Dermatol. 2016, 41: 573-75. IF 1.3

(69) Horváth O, Varga R, Kaneda M, **Schmidt E**, Ruzicka T, Sárdy M. Diagnostic performance of the MESACUP Anti-Skin Profile ELISA. Eur J Dermatol 2016, 26: 56-63. IF 2.0

(70) Griss J, Stingl G, **Schmidt E**, Bangert C. A rare bullous variant of dermatitis herpetiformis. Br J Dermatol 2016, 174: 231-32. IF 4.7

(71) Goyal N, Rao R, Balachandran C, Pai S, Bhogal BS, **Schmidt E**, Zillikens D. Childhood epidermolysis bullosa acquisita: confirmation of diagnosis by skin deficient in type VII collagen, enzyme-linked immunosorbent assay, and immunoblotting. Indian J Dermatol 2016, 61: 329-32. IF 1.9

(72) Akbarzadeh R, Yu X, Vogl T, Ludwig R, **Schmidt E**, Zillikens D, Petersen F. Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid. J Dermatol Sci 2016, 81: 165-72. IF 3.7

(73) Galli-Novak E, Mook SC, Büning J, **Schmidt E**, Zillikens D, Thaci D, Ludwig R. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. J Eur Acad Dermatoal Venereol 2016, 30: 191-192. IF 3.5

(74) Schulze F, Neumann K, Recke A, Zillikens D, Linder R, **Schmidt E**. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015, 135: 1445-47. IF 6.9

(75) Sadeghi H, Lockmann A, Hund AC, Samavedam U, Pipi E, Vafia K, Hauenschild E, Kalies K, Pas HH, Jonkman MF, Iwata H, Recke A, Schön M, Zillikens D, **Schmidt E***, Ludwig R*. Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules. J Immunol 2015, 194: 3656-63. IF 5.4. * equal contribution.

(76) **Schmidt E**, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, Hofmann S, Hunzelmann N, Kern JS, Kramer H, Orzechowski HD, Pfeiffer C, Schuster V, Sporbeck B, Sticherling M, Worm M, Zillikens D, Nast A. S2k Guidelines for diagnosis of pemphigus vulgaris / foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015, 13: 713-727. IF 2.5

(77) Recke A, Vidarsson G, Ludwig R, Freitag M, Möller S, Vonthein R, Schellenberger J, Haase O, Görg S, Nebel A, Flachsbart F, Schreiber S, Lieb W, Gläser R, Benoit S, Sárdy M, Eming R, Hertl M, Zillikens D, König I, **Schmidt E**, Ibrahim S, and the German AIBD Genetic Study Group. Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseases. J Autoimmun 2015, 61: 36-44. IF 7.0

(78) Eming R, Sticherling M, Hofmann S, Hunzelmann N, Kern JS, Kramer H, Pfeiffer C, Schuster V, Zillikens D, Goebeler M, Hertl M, Nast A, Orzechowski HD, Sárdy M, **Schmidt E**, Sitaru C, Sporbeck B, Worm M. S2k Guidelines for the treatment of pemphigus vulgaris / foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015, 13: 833-845. IF 2.5

(79) Sadeghi H, Gupta Y, Möller S, Samavedam UK, Behnen M, Kasprick A, Bieber K, Müller S, Kalies k, de Castro Marques A, Recke A, **Schmidt E**, Zillikens D, Laskay T, Mariani J, Ibrahim S, Ludwig R. The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita. J Pathol 2015, 237: 111-122. IF 6.8

(80) Hirose M, Schilf P, Benoit S, Eming R, Gläser R, Homey B, Kunz M, Nebel A, Peitsch WK, Pföhler C, Sárdy M, Schreiber S, Zillikens D, **Schmidt E**, Ibrahim SM; German AIBD Genetic Study Group. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. Exp Dermatol 2015, 24: 715-7. IF 3.7

(81) Prüßmann W, Prüßmann J, Koga H, Recke A, Iwata H, Juhl D, Görg S, Henschler R, Hashimoto T, **Schmidt E**, Zillikens D, Ibrahim S, Ludwig R. Prevalence of pemphigus and pemphigoid autoantibodies in the general population. Orphanet J Rare Dis 2015, 10:63. IF 4.0

(82) Kunz M, König I, Schillert A, Kruppa J, Ziegler A, Grallert H, Müller-Nurasyid M, Lieb W, Franke A, Ranki A, Panelius J, Koskenmies S, Hasan T, Kere J, Rönn A, Simon JC,

Schmidt E, Wenzel J, Tüting T, Landsberg J, Zeller T, Blankenberg S, Gläser R, Patsinakidis N, Kuhn A, Ibrahim S. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol 2015, 24: 510-515. IF 3.7

(83) Haase O, Alnebari R, Eldarouti MA, Abd El Hady M, Dorgham D, El-Nabarawy E, El Din Mahmoud SB, Mosaad El Sayed H, Darwish M, Abbas F, Salah S, Mosaad Y, El Chennawy F, Al Mongy S, Abdelaziz AM, Abd El Gaber S, Hertl M, Eming R, Recke A, Möller S, **Schmidt E**, Zillikens D, Ibrahim S. Association with HLA-DRB1 in Egyptian and German pemphigus vulgaris patients. Tissue Antigens 2015, 85: 283-86. IF 2.4

(84) Agrawal P, George R, Thomas M, Has C, Pas H, **Schmidt E**, Leverkus M. A childhood subepidermal autoimmune bullous disease resembling mechanobullous epidermolysis bullosa acquisita. Br J Dermatol 2015, 173:227-234. IF 4.3

(85) van Beek N, Patsatsi A, Gupta Y, Möller S, Freitag M, Lemcke S, Recke A, Zillikens D, **Schmidt E**, Ibrahim S. A family with atypical Hailey Hailey disease- is there more to the underlying genetics than ATP2C1? Plos One 2015, 10: e121253. IF 3.7

(86) Vorobyev A, Ujiie H, Recke A, Buijsrogge J, Jonkman M, Iwata H, Hashimoto T, Kim SC, Kim JH, Groves R, Samavedam U, Gupta Y, **Schmidt E**, Zillikens D, Shimizu H, Ludwig R. Autoantibodies to multiple epitopes on the non-collagenous-1 domain of type VII collagen induce blisters. J Invest Dermatol 2015, 135: 1565-73. IF 7.2

(87) Langenhan J, Mersmann M, Dworschak J, **Schmidt E**, Probst C, Stöcker W. Track Z: Novel developments in the diagnosis and treatment of autoimmune blistering diseases. Biomed Tech (Berl) 2015; 60: s407-25. IF 1.2

(88) Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J, Goletz S, Zillikens D, Ludwig R, **Schmidt E**. FcγRIII and FcγRIV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 2014, 184: 2185-96. IF 4.8

(89) Kasperkiewicz M, Süfke S, **Schmidt E**, Zillikens D. IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatology 2014, 150: 1350-51. IF 4.8

(90) Miyamoto J, Bockle BC, Zillikens D, **Schmidt E**, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. JAMA Dermatology 2014, 150: 1120-1122. IF 4.8

(91) Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D, **Schmidt E**. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol 2014, 71: 2018-20. IF 5.0

(92) Van Beek N, Dohse A, Riechert F, Krull V, Recke A, Zillikens D, **Schmidt E**. Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals, and blood donors prospectively recruited. Br J Dermatol 2014, 170: 943-7. IF 4.1

(93) Prüßmann J, Prüßmann W, Recke A, Rentzsch K, Juhl D, Henschler R, Müller S, Lamprecht P, **Schmidt E**, Csernok E, Görg S, Stöcker W, Zillikens D, Ibrahim S, Ludwig R. Co-occurrence of autoantibodies in healthy blood donors. Exp Dermatol 2014, 23: 519-21. IF 4.1

(94) Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, Stöcker W, Westermann J, Recke A, Zillikens D, **Schmidt E**, Probst C. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol 2014, 23: 253-9. IF 4.1

(95) Ludwig R, Borradori L, Diaz L, Hashimoto T, Hertl M, Ibrahim S, Jonkman M, Kitajima Yasuo, Murrell D, **Schmidt E**, Shimizu H, Stanley J, Woodley D, Zillikens D. From epidemiology and genetics to diagnostics, outcome measures and novel treatments in autoimmune bullous diseases. J Invest Dermatol 2014, 134: 2298-300. IF 7.2

(96) Yu X, Zheng J, Collin M, **Schmidt E**, Zillikens D, Petersen F. EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils. Plos One 2014, 9: e85317. IF3.7

(97) Samavedam U, Iwata H, Müller S, Schulze FS, Recke A, **Schmidt E**, Zillikens D, Ludwig R. GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita. J Immunol 2014, 192: 559-71. IF 5.5

(98) Sayar B, Rüegg S, **Schmidt E**, Sibilia M, Siffert M, Suter M, Galichet A, Mueller E. EGFR inhibiters erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. Exp Dermatol 2014, 23: 33-8. IF 4.1

(99) Komorowski L, Müller R, Vorobyev A, Probst C, Recke A, Jonkman MF, Hashimoto T, Kim SC, Groves R, Ludwig R, Zillikens D, Stöcker W, **Schmidt E**. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol 2013, 68: 89-95. IF 4.9

(100) Schulze F, van Beek N, Terheyden P, Zillikens D, **Schmidt E**. Concomitant bullous pemphigoid and dermatitis herpetiformis. Dermatology 2013, 226: 217-21. IF 2.0

(101) Van Beek N, Schumacher N, Haase O, Zilikens D, Kahle B, **Schmidt E**. Diagnose eines Antiphospholipidsyndroms bei Ulcus cruris unter Marcumartherapie. Hautarzt 2013, 64: 666-70. IF 0.5

(102) Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski p, Ludwig R, Zillikens D, **Schmidt E**, Fischer T, Kasperkiewicz M. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. Plos One 2013, 8:e70496. IF3.7

(103) Hellberg L, Samavedam U, Holdorf K, Hänsel M, Recke A, Beckmann T, Steinhorst K, Boehncke WH, Kirchner T, Möckel N, Solbach W, Zillikens D, **Schmidt E**, Ludwig R, Laskay T. Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. J Invest Dermatol 2013, 133:2390-99. IF 6.2

(104) Spindler V, Rötzer V, Dehner C, Kempf B, Gliem M, Hartlieb E, Harms GS, **Schmidt E**, Waschke J. Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest 2013, 123: 800-811. IF 12.8

(105) Tukaj S, **Schmidt E**, Ludwig R, Zillikens D, Tukaj C, Kasperkiewicz. Vitamin D status in bullous pemphigoid patients. Br J Dermatol 2013, 168: 873-74. IF 3.8

(106) Majima Y, Yagi H, Tateishi C, Groth S, **Schmidt E**, Zillikens D, Koga H, Hashimoto T, Tokura Y. A successful treatment with ustekinumab in a case of anti-laminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol 2013, 168: 1367-69. IF 3.8

(107) Kamiya K, Aoyama Y, Kawase K, **Schmidt E**, Zillikens D, Kitajima Y, Iwatsuki K. Case of subepidermal blistering disease with autoantibodies to both laminin-γ1 and laminin-α3. J Dermatol 2013; 40: 491-2. IF 2.1

(108) Kim JH, Kim YH, Kim S, Noh EB, Kim SE, Vorobyev A, **Schmidt E**, Zillikens D, Kim SC. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol 2013, 27: 224-230. IF 2.7

(109) Hirose M, Vafia K, Kalies K, Groth S, Westermann J, Zillikens D, Ludwig R, Collin M, **Schmidt E**. Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII. J Autoimmun 2012, 39: 304-14. IF 8.1

(110) Vafia K, Groth S, Beckmann T, Hirose M, Dworschak J, Recke A, Ludwig R, Hashimoto T, Zillikens D, **Schmidt E**. Pathogenicity of autoantibodies in anti-p200 pemphigoid. Plos One 2012, 7: e41769. IF 3.7

(111) van Beek N, Rentzsch K, Probst C, Komorowski L, Kasperkiewicz M, Fechner K, Bloecker IM, Zillikens D, Stöcker W, **Schmidt E**. Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012, 7:49. IF 4.3

(112) Groth S, Vafia K, Recke A, Dähnrich C, Zillikens D, Stöcker W, Kuhn A, **Schmidt E**. Antibodies to the C-terminus of laminin γ1 are present in a distinct subgroup of patients with systemic and cutaneous lupus erythematosus. Lupus 2012, 21: 1482-83. IF 2.8

(113) Monshi B, Groth S, Richter L, **Schmidt E**, Zillikens D, Rappersberger K. A long-term study of a patient with anti-p200 pemphigoid - correlation of autoantibody levels with disease activity and an example of epitope spreading. Br J Dermatol 2012, 167: 1179-1183. IF 3.8

(114) Kamphausen I, Schulze F, **Schmidt E**, Zillikens D, Kunz M. Treatment of severe pemphigus vulgaris with adjuvant rituximab and immunoadsorption. Eur J Dermatol 2012, 22: 786-87. IF 1.8

(115) Samavedam U, Kalies K, Scheller J, Gupta Y, Jonkman MF, **Schmidt E**, Westermann J, Zillikens D, Rose-John S, Ludwig R. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 2012, 40: 74-85. IF 8.1

(116) Kasperkiewicz M. Nimmerjahn F, Wende S, Hirose M, Iwata H, Jonkman M, Samavedam U, Gupta Y, Möller S, Rentz E, Hellberg L, Kalies K, Yu Y, **Schmidt E**, Häsler R, Laskay T, Westermann J, Köhl J, Zillikens D, Ludwig R. Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury. J Pathol 2012, 228: 8-19. IF 7.6

(117) Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, von Wussow P, Hertl M, Zillikens D, Freivogel K, Dörner T, **Schmidt E**. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 2012, 10: 727-32. IF 1.5

(118) Blöcker IM, Dähnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stöcker W, Zillikens D, **Schmidt E**. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol 2012, 166: 964-70. IF 3.8

(119) Dworschak J, Recke A, Freitag M, Ludwig R, Langenhan J, Kreuzer OJ, Zillikens D, **Schmidt E**. Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides. J Dermatol Sci 2012, 65: 102-9. IF 3.5

(120) Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, Israeli S, Sagiv N, Martinez H, Katz O, Baum S, Barzilai A, Trau H, Murrell DF, Bergman R, Hertl M, Rosenberg S, Nöthen MM, Skorecki K, **Schmidt E**, Zillikens D, Darvasi A, Geiger D, Rosset S, Ibrahim SM, Sprecher E. A population-specific variant in *ST18*, encoding a pro-apoptotic molecule, predisposes to pemphigus vulgaris; J Invest Dermatol 2012, 132: 1798-805. IF 6.2

(121) Ludwig R, Müller S, de Castro Marques A, Recke A, **Schmidt E**, Zillikens D, Möller S, Ibrahim S. Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2012, 132: 1409-15. IF 6.2

(122) van Beek N, Knuth- Rehr D, Altmeyer P, Assaf C, Babilas , Bayerl C, Benoit S, Dippel E, Effendy I, Eming R, Fischer M, Glaenz T, Gläser R, Goebeler M, Gollnick H, Götze S, Gross P, Hadaschik E, Herbst R, Hermes B, Homey B, Hunzelmann N, Jünger M, Kapp M, Kern JS, Körber A, Luger T, Mechtel D, Megahed M, Moll I, Peters KP, Pfeiffer C, Ring J, Röcken M, Sárdy M, Seitz C, Stadler R, Steinbrink K, Sticherling M, Szeimies RM, Tronnier M, Ulrich J, Vogt T, Wagner N, Welzel J, Wenzel J, Wozel G, Zouboulis CC, Zillikens D, **Schmidt E**. Diagnostic of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges 2012, 10: 492-99. IF 1.4

(123) Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha A, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman M, Pandya A, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM, **Schmidt E**, Shimizu H, Zone J, Swerlick R, Culton D, Mimouni D, Lipozencic J, Bincie B, Bystryn JC, Werth VP. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012, 66: 479-85. IF 4.9

(124) Westermann L, Huegel R; Meier M, Zillikens D, Glaeser R, **Schmidt E**. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol 2012, 39: 168-71. IF 1.8

(125) Schulz S, Deuster D, **Schmidt E**, Bonsmann G, Beissert S. Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid. Int J Dermatol 2011, 50: 1129-31. IF 1.3

(126) Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, Zillikens D, **Schmidt E**. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone, and azathioprine/ mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012, 166: 154-60. IF 4.4

(127) Spindler V, Endlich A, Hartlieb E, Vielmuth E, **Schmidt E**, Waschke J. The extent of desmoglein 3 depletion in pemphigus vulgaris is dependent on Ca^{2+}-induced differentiation – a role in suprabasal epidermal skin splitting? Am J Pathol 2011, 179: 1905-16. IF 4.8

(128) Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM Somlai C, Westermann J, **Schmidt E**, Zillikens D, Ludwig RJ, Orosz A. Heat shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that non-malignant plasma cells are not therapeutic targets. Blood 2011, 117: 135-42. IF 9.9

(129) Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K, Westermann J, Zillikens D, **Schmidt E**, Ludwig R. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 2011, 187: 1176-83. IF 5.8

(130) Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, UngerL, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C,Weinerth J, Holle J, Muller-Ladner U, Koenig R, Fiehn C, Burgwinkel P, Budde K,Soerensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M,Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, **Schmidt E**, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M,Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011, 13: R75. IF 4.4

(131) Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, **Schmidt E**, Zillikens D, Shirakata Y, Hashimoto K, Kitajima Y, Amagai M. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011, 62: 169-75. IF 3.7

(132) Recke A, Shimanovich I, Steven P, Westermann L, Zillikens D, **Schmidt E**. Therapieresistentes Anti-Laminin 332-Schleimhautpemphigoid: Komplette Remission unter adjuvanter Immunapherese und Rituximab. Hautarzt 2011, 62: 852-8. IF 0.6

(133) Haase O, Moser A, Rose C, Kurth A, Zillikens D, **Schmidt E**. Generalised cowpox infection in a patient with Darier's disease. Br J Dermatol 2011, 164: 1116-8. IF 3.7

(134) Westermann L, Dilling A, Pajouh P, Rose C, **Schmidt E**. Longstanding painful hemorrhagic vesicles and erosions on the lower leg. Arch Dermatol 2011, 147:235-40. IF 3.9

(135) Groth S, Recke A, Vafia K, Ludwig R, Hashimoto T, Zillikens D, **Schmidt E**. Development of a simple ELISA for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011, 164:76-82. IF 3.7

(136) Kasperkiewicz M, Shimanovich I, Ludwig R, Rose C, Zillikens D, **Schmidt E**. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011, 65: 552-8. IF 4.0

(137) Leverkus M, Ambach A, Hoefeld-Fegeler M, Kohlhase J, **Schmidt E**, Schumann H, Has C, Gollnick H. Late onset inversa recessive dystrophic epidermolysis bullosa caused by glycine substitutions in collagen type VII. Br J Dermatol 2011, 164:1104-6. IF 3.7

(138) Saw V, Offiah I, Galatowicz G, **Schmidt E**, Zillikens D, Dart J, Calder VL, Daniels JT. Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. Am J Pathol 2011, 178: 187-97. IF 4.8

(139) Ludwig RJ, Recke A, Bieber K, Müller S, de Castro Marques A, Banczyk D, Hirose M, Kasperkiewicz M, Ishii N, **Schmidt E**, Westermann J, Zillikens D, Ibrahim SM. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol 2011, 131: 167-76. IF 6.3

(140) Kasperkiewicz M, **Schmidt E**, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, Reich K, Ludwig R, Zillikens D. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study. J Allergy Clin Immun 2011, 127: 267-70. IF 11.0

(141) Spindler V, Vielmuth F**, Schmidt E**, Rubenstein DS, Waschke J. Protective endogenous cAMP signaling triggered by pemphigus autoantibodies. J Immunol 2010, 185:6831-8. IF 5.7

(142) Kubisch I, Diessenbacher P, **Schmidt E**, Gollnick H, Leverkus M. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis. Am J Clin Dermatol 2010, 11: 289-93. IF 2.0

(143) Kasperkiewicz M, Hirose M, Recke A, **Schmidt E**, Zillikens D, Ludwig RJ. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. Br J Dermatol 2010, 162: 1064-70. IF 4.3

(144) Kasperkiewicz M, Meier M, Zillikens D, **Schmidt E**. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 2010, 220:259-63. IF 2.7

(145) Kasperkiewicz M, Hoppe U, Zillikens D, **Schmidt E**. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol 2010, 25:614-17. IF 1.3

(146) Zimmermann J, Bahmer F, Rose C, Zillikens D, **Schmidt E**. Clinical and immunpathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010, 8:598-603. IF 1.5

(147) **Schmidt E**, Dähnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stöcker W, Hashimoto T, Bröcker EB, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies to desmoglein 1 and 3: Correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010, 19: 458-63. IF 4.2

(148) Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Schulze-Lohoff E, Becker M, Sunderkoetter C; Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, **Schmidt E**, Lehmann P, Foeldvári I, Reichenberger F, Gross L, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V, Buslau M, Distler J, Sticherling M. Riemekasten G. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations: an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford). 2009; 48: 70-73. IF 4.1

(149) Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G; Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Mierau R, Hein R, Hinrichs R, Szeimies RM, Karrer S, Muller AM, Meyering R, Seitz C, **Schmidt E**, Lehmann P, Foeldvari I, Reichenberger F, Gross L, Kuhn A, Haust M, Reich K, Becker M, Saar P, Schmeiser T, Fierlbeck G, Kotter I, Lorenz HM, Blank N, Grafenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V, Buslau M, Distler J, Sticherling M. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009;160: 835-43. IF 4.3

(150) Probst C, Schlumberger W, Stöcker W, Recke A, **Schmidt E**, Hashimoto T, Zhu XJ,Zillikens D, Komorowski L. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009, 410: 13-8. IF 2.5

(151) Riederle HM, **Schmidt E**, Eck M, Meyer-ter-Vehn T, Geerling G. Tumour of the conjunctiva with diffuse cicatrisation. Ophthalmologe. 2009,106: 56-9. IF 0.8

(152) Spindler V, Heupel WM, Efthymiadis A, **Schmidt E**, Eming R, Rankl C, Hinterdorfer P, Müller T, Drenckhahn D, Waschke J. Desmocollin 3-mediated binding Is crucial for keratinocyte cohesion and is impaired in pemphigus. J Biol Chem 2009; 284: 30556-64. IF 5.3

(153) Heupel WM, Mueller TD, Efthymiadis A, **Schmidt E**, Drenckhahn D, Waschke J. Peptides targeting the desmoglein 3 adhesive interface prevent autoantibody-induced acantholysis in pemphigus. J Biol Chem 2009; 284: 8589-95. IF 5.3

(154) Heupel WM, Engerer P, **Schmidt E**, Waschke J. Pemphigus vulgaris IgG cause loss of desmoglein-mediated adhesion and keratinocyte dissociation independent of epidermal growth factor receptor. Am J Pathol. 2009; 174: 475-85. IF 5.7

(155) Recke A, Rose C, **Schmidt E**, Bröcker EB, Zillikens D, Sitaru C. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B cell epitope spreading without IgG subclass shifting. J Am Acad Dermatol 2009; 61: 333-36. IF 4.1

(156) Schumann T, **Schmidt E**, Booken M, Goerdt S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab. Acta Dermatol Venereol (Stockh.) 2009, 89: 101-2. IF 3.0

(157) Rose C, **Schmidt E**, Kerstan A, Thoma-Uszynski S, Wesselmann U, Käsbohrer U, Zillikens D, Shimanovich I. Histopathology of anti-laminin 5 mucous membrane pemphigoid. J Am Acad Dermatol. 2009, 61: 433-40. IF 4.1

(158) Bertram F, Bröcker EB, Zillikens D, **Schmidt E**. Prospektive Untersuchung der Inzidenz blasenbildender Autoimmundermatosen in Unterfranken. J Dtsch Dermatol Ges 2009, 5: 434-40. IF 1.4

(159) **Schmidt E**, Benoit S, Bröcker E. Umbilical bullous pemphigoid. Acta Dermatol Venereol (Stockh.), 2009, 89: 419-20. IF 3.0

(160) **Schmidt E**, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009;132: 334-41. IF 3.9

(161) **Schmidt E**, Gutberlet J, Siegmund D, Berg D, Wajant H, Waschke J. Apoptosis is not required for acantholysis in pemphigus vulgaris. Am J Physiol Cell Physiol 2009; 296, C162-172. IF 4.0

(162) Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P,Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, **Schmidt E**, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-92. IF 4.1

(163) Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, **Schmidt E**, Shimanovich I, Sticherling M, Wolff-Franke S. Empfehlungen für den Einsatz von Rituximab (anti-CD20 -Antikörper) bei bullösen Autoimmundermatosen. J Dtsch Dermatol Ges 2008; 6: 366-74. IF 1.4

(164) Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, **Schmidt E**, Shimanovich I, Sticherling M, Ziller M. Recommendations fort the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881-7. IF 1.4

(165) Sitaru C, Dähnrich D, Probst C, Komorowski L, Blöckere I, **Schmidt E**, Schlumberger W, Rose C, Stöcker W, Zillikens D. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770-777. IF 3.0

(166) Kerstan A, Goebeler M, **Schmidt E**, Bröcker EB, Schön P. Lupus erythematosus profundus in an 8-year-old child. J Eur Acad Dermatol Venerol 2007; 21: 132-3. IF 1.4

(167) **Schmidt E**, Tony HP, Bröcker EB, Kneitz C. Sun-induced life-threatening lupus-nephritis. Ann N Y Acad Sci 2007; 1108: 35-40. IF 1.7

(168) **Schmidt E**, Vetter-Kauczok CS, Kolb-Mäurer A, Mooi W, Bröcker EB. Indurated swelling of the scrotum in a 65-year-old man. Clin Exp Dermatol 2007; 32: 588-589. IF 1.5

(169) **Schmidt E**, Seitz CS. Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6. IF 3.6

(170) Mulyowa GK, Jaeger G, Sitaru C, Bröcker E-B, Zillikens D, **Schmidt E**. Scarring autoimmune bullous disease in an Ugandan patient with autoantibodies to BP180, BP230, and Laminin 5. J Am Acad Dermatol 2006; 54: S43-46. IF 2.6

(171) Mulyowa GK, Jaeger G, Kabakyenga J, Bröcker EB, Zillikens D, **Schmidt E**. Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol 2006; 45:1047-52. IF 1.0

(172) Shimanovich I, Herzog S, **Schmidt E**, Klinker E, Opitz A, Bröcker EB, Goebeler M, Zillikens D. Improved protocol for treatment of pemphigus vulgaris with protein A immunadsorption. Clin Exp Dermatol 2006; 31: 768-74. IF 1.3

(173) Benoit S, **Schmidt E**, Sitaru S, Rose C, Goebeler M, Bröcker E-B, Zillikens D. Schleimhautpemphigoid mit Autoantikörpern gegen Laminin 5. J Dtsch Dermatol Ges 2006; 4: 41-44. IF 1.4

(174) **Schmidt E**, Wehr B, Wolf K, Sitaru C, Bröcker EB, Zillikens D. Localisation of Bullous Pemphigoid Antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium. Arch Dermatol Res 2006; 298: 283-90. IF 1.6

(175) **Schmidt E**, Weissbrich B, Bröcker E-B, Fleischer K, Goebeler M, Stich G. Orf followed by erythema multiforme. J Eur Acad Dermatol Venerol 2006; 18: 612-13. IF 1.5

(176) **Schmidt E**, Benoit S, Bröcker E-B, Zillikens D, Goebeler M. Successful treatment of recalcitrant epidermolysis bullosa acquisita with rituximab. Arch Dermatol 2006; 142: 47-50. IF 2.9

(177) **Schmidt E**, Herzog S, Bröcker E-B, Zillikens D, Goebeler M. Rituximab induced long-standing remission in a 14-year-old boy with treatment-resistant pemphigus vulgaris. Br J Dermatol 2005; 153: 449-451. IF 3.0

(178) **Schmidt E,** Kraensel R, Goebeler M, Sinkgraven R, Bröcker EB, Rzany B, Zillikens D. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005, 76: 205-209. IF 0.9

(179) Herzog S, **Schmidt E**, Goebeler M, Bröcker EB, Zillikens D. Serum Levels of Autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Dermatol Venereol (Stockh.) 2004: 84: 48-52. IF 1.9

(180) **Schmidt E**, Rose C, Mulyowa GK, Jäger G. Dermatologie an der Universitäts-Hautlinik Mbarara, Uganda. J Dtsch Dermatol Ges 2004; 2: 920-926. IF 1.4

(181) **Schmidt E**, Wehr B, Tabengwa EM, Reimer S, Bröcker EB, Zillikens D. Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin Exp Immunol 2004; 135: 497-504. IF 2.5

(182) Benoit S, Rose C, **Schmidt E**, Zillikens D. Persistierende Papulopusteln im Gesicht eines 21-jährigen. J Dtsch Dermatol Ges 2003, 1: 907-909. IF 1.4

(183) **Schmidt E**, Rose C, Benoit S, Hamm H. Multiple Papeln und Knoten am Skrotum eines 34jährigen Patienten. J Dtsch Dermatol Ges 2003, 1: 395-397. IF 1.4

(184) **Schmidt E**, Kromminga A, Kürschner M, Zimmermann H, Katsen AD, Bröcker EB, Zillikens D, Zimmermann U, Sukhorukov VL. Trehalose conserves expression of bullous pemphigoid antigen 180 during desiccation and freezing. J Immunol Meth 2003, 275: 179-190. IF 2.7

(185) **Schmidt E**, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, BM Taleghoni, Bröcker EB, Zillikens D. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003, 148: 1222-1229. IF 2.7

(186) Kromminga A, Sitaru C, Meyer J, Arndt R, **Schmidt E**, Christophers E, Bröcker EB, Zillikens D. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain. J Dermatol Sci 2002; 28: 68-75. IF 1.6

(187) Sitaru C, **Schmidt E**, Petermann, Munteanu LS, Bröcker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002; 118: 664-671. IF 4.3

(188) **Schmidt E**, Kromminga A, Mimietz S, Leinfelder U, Sitaru C, Bröcker EB, Zillikens D, Zimmermann U. A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. J Autoimmunity 2002, 18: 299-309. IF 2.3

(189) **Schmidt E**, Höpfner B, Chen M, Kuhn C, Weber L, Bröcker EB, Bruckner-Tuderman L, Zillikens D. Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. Br J Dermatol 2002, 147: 592-597. IF 2.7

(190) **Schmidt E**, Sitaru C, Schubert B, Wesselmann U, Kromminga A, Bröcker EB, Zillikens D. Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared to classical bullous pemphigoid. J Am Acad Dermatol 2002, 47: 133-136. IF 2.8

(191) Zillikens D, **Schmidt E**, Reimer S, Chimanovitch I, Hardt-Weinelt K, Rose C, Bröcker E-B, Koch M, Böhnke WH. Antibodies to desmoglein 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. J Pathol 2001; 193: 117-124. IF 4.9

(192) **Schmidt E**, Leinfelder U, Geßner P, Zillikens D, Bröcker EB, Zimmermann U. $CD19^+$ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Meth 2001; 255: 93-102. IF 2.7

(193) **Schmidt E**, Skrobek C, Kromminga A, Hashimoto T, Messer G, Bröcker E-B, Yancey KB, Zillikens D. Cicatricial Pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of BP180. Br J Dermatol 2001; 145: 778-783. IF 2.6

(194) **Schmidt E**, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001; 142: 157-162. IF 2.3

(195) Döpp R, **Schmidt E**, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577-83. IF 2.5

(196) **Schmidt E.** Dermatologie im Sahel: Eindrücke einer Hospitation im Tschad. Dt Dermatol 2000, 5: 357-359. IF 0.25

(197) **Schmidt E**, Reimer S, Kruse N, Jainta S, Bröcker E-B, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated with bullous pemphigoid release IL-6 and IL-8 from cultured human keratinocytes. J Invest Dermatol 2000, 115: 842-848. IF 4.5

(198) **Schmidt E**, Obe K, Bröcker E-B, Zillikens D. Levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000, 136: 174-178. IF 3.5

(199) Zillikens D, Caux F, Mascaro JM, Prost C, Wesselmann U, **Schmidt E**, Prost C, Callen JP, Bröcker EB, Diaz LA, Giudice GJ. Antibodies in lichen planus pemphigoides react with a

novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113: 117-121. IF 4.5

(200) Zillikens D, Herzele K, Georgi M, **Schmidt E**, Chimanovitch I, Schumann H, Mascaro JM Jr, Diaz LA, Bruckner-Tuderman L, Bröcker EB, Giudice GJ. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP180. J Invest Dermatol 1999; 113: 947-53. IF 4.5

(201) Kippes W, **Schmidt E**, Roth A, Rzany B, Bröcker EB, Zillikens D. Immunopathologic changes in 115 patients with bullous pemphigoid. Hautarzt. 1999; 50: 866-72. IF 0.5

(202) Chimanovitch I, **Schmidt E**, Messer G, Döpp R, Portscht K, Bröcker EB, Giudice GJ, Zillikens D. IgG_1 and IgG_3 are the major immunoglobulin subclasses targeting epitopes within BP180 NC16A in pemphigoid gestationis. J Invest Dermatol 1999; 113: 10-142. IF 4.5

(203) Leverkus M, **Schmidt E**, Lazarova Z, Bröcker EB, Yancey KB, Zillikens D. Anti-epiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring subepidermal bullous diseases. Arch Dermatol 1999, 135: 1091-1098. IF 3.5

(204) **Schmidt E**, Herzele K, Schumann H, Wesselmann U, Chimanovitch I, Bruckner-Tuderman L, Bröcker E-B, Giudice GJ, Zillikens D. Linear IgA disease with circulating IgA antibodies against the NC16A domain of BP180. Br J Dermatol 1999; 140: 964-967. IF 2.6

(205) **Schmidt E**, Ambach A, Bastian B, Bröcker E-B, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy controls. J Am Acad Dermatol 1996; 34: 310-313. IF 2.8

(206) **Schmidt E**, Bastian B, Dummer R, Tony HP, Bröcker E-B, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996; 288: 353-357. IF 1.6

(207) **Schmidt E**, Mittnacht A, Schömig H, Dummer R, Bröcker E-B, Zillikens D. Detection of IL-1α, IL-1β, and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. J Dermatol Sci 1996; 11: 142-147. IF 1.6

(208) **Schmidt E**, Bröcker E-B, Zillikens. High levels of soluble CD23 in blister fluid of bullous pemphigoid. Arch Dermatol 1995; 131: 966-967. IF 3.5

IF total: 974.5

Reviews in peer-reveiwed journals

(1) **Schmidt E**, Kasperkiewicz M, Joly P. Pemphigus, in press. IF 59.1

(2) Sadik C, **Schmidt E**. Resolution in bullous pemphigoid. Semin Immunopathol, in press. IF 6.8

(3) van Beek N, Zillikens D, **Schmidt E**. Therapie des Pemphigus. Hautarzt 2019, 70: 243-53. IF 0.6

(4) Eming R, **Schmidt E**. Bullöse Autoimmundermatosen: Update zu Therapien und selteneren Entitäten (editorial). Hautarzt 2019, 70: 234-35. IF 0.6

(5) van Beek N, Zillikens D, **Schmidt E**. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges 2018, 16: 1077-92. IF 3.9

(6) Witte M, Zillikens D, **Schmidt E**. Diagnosis of autoimmune blistering diseases. Front Med 2018, 5: 296. IF 3.1

(7) Holtsche M, Zillikens D, **Schmidt E**. Mucous membrane pemphigoid. Hautarzt 2018: 67-83. IF 0.7

(8) Amber KT, Murrell DF, **Schmidt E**, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018, 54: 26-51. IF 7.3

(9) Goletz S; Zillikens D, **Schmidt E**. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol 2017, 26: 1154-62. IF 2.6

(10) Vorobyev A, Ludwig R, **Schmidt E.** Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol 2017, 13: 157-69. IF 3.4

(11) Försti AK, Huilaja L, **Schmidt E**, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid - more than skin deep? Exp Dermatol 2017, 26: 1228-34. IF 2.6

(12) Ludwig R, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan S, Komorowski L, Luo J, Marques O, Hammers CM, Lindstrom JM, Lamprecht P, Fischer A, Riemekasten G, Tersteeg C, Sondermann P, Rapoport B, Wandinger KP, Probst C, El Beidaq A, **Schmidt E**, Verkman A, Manz R, Nimmerjahn F. Mechanisms of autoantibody-induced pathology. Front Immunol 2017, 8: 603. IF 5.5

(13) Lima AL, Zillikens D, **Schmidt E.** Klinik und Diagnostik bullöser Autoimmundermatosen: wenn die Schleimhaut nicht mehr heilen will. ZM 2016, 106: 72-84. IF 0.25

(14) Van Beek N, Schulze FS, Zillikens D, **Schmidt E.** IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol 2016, 12: 267-77. IF 3.3

(15) Kasperkiewicz M, Sadik C, Bieber K, Ibrahim S, Manz R, **Schmidt E**, Zillikens D, Ludwig R. Epidermolysis bullosa acquisita: From pathophysiology to novel therapeutic options. J Invest Dermatol 2016, 136: 24-33. IF 6.9

(16) Stockinger T, Richter L, Kanzler M, Melichart-Kotik M, Pas H, Derfler K, **Schmidt E**, Rappersberger K. Systemischer Lupus erythematodes: ungewöhnliche Hautmaifestationen. Hautarzt 2016, 67: 970-81. IF 0.6

(17) Vorobyev A, Hammers C, Zillikens D, **Schmidt E**. Bullöse Autoimmundermatosen: Moderne serologische Testverfahren ermöglichen genaue Diagnose. Dtsch Dermatol 2015, 63: 738-745. IF 0.25

(18) Goletz S, Hashimoto T, Zillikens D, **Schmidt E**. Anti-p200 pemphigoid. J Am Acad Dermatol 2014, 71: 185-91. IF 4.9

(19) Schwieger-Briel A, Moellmann C, Mattulat B, Schauer F, Kiritsi D, **Schmidt E**, Sitaru C, Ott H, Kern JS. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. Orphanet J Rare Dis. 2014; 9: 185. IF 3.9

(20) Hammers CM, **Schmidt E**, Zillikens D. Blasenbildende Autoimmunerkrankungen der Haut - diagnostische und therapeutische Aspekte. DMW 2014, 139: 1473-77. IF 0.25

(21) **Schmidt E**, Zillikens D. Pemphigoid diseases. Lancet 2013, 381: 320-32. IF 39.2

(22) Schulze F, Kasperkiewicz M, Zillikens D, **Schmidt E**. Bullöses Pemphigoid. Hautarzt 2013, 64: 931-43. IF 0.5

(23) Ludwig R, Kalies K, Köhl J, Zillikens D, **Schmidt E**. Emerging treatments for pemphigoid diseases. Trends Mol Med 2013, 19: 501-12. IF 9.6

(24) Hammers C, Lunardon L, **Schmidt E**, Zillikens D. Contemporary management of pemphigus. Exp Opin Orphan Drugs 2013, 1: 295-314. IF 0.25

(25) Meyersburg D, **Schmidt E**, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial 2012, 16: 311-20. IF1.5

(26) Kasperkiewicz, Zillikens D, **Schmidt E**. Pemphigoid diseases: pathogenesis, diagnosis and treatment. Autoimmunity 2012, 45: 55-70. IF 2.8

(27) **Schmidt E**, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011, 29: 427-38. IF 2.2

(28) **Schmidt E**, Zillikens D. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. Dermatol Clin 2011, 29: 663-71. IF 2.2

(29) Kasperkiewicz M, **Schmidt E**, Zillikens D. Current therapy of pemphigus group. Dermatol Clin 2011, 30: 84-94. IF 2.2

(30) **Schmidt E**, Zillikens D. Diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 2011, 108: 399-405. IF 2.9

(31) Haase O, **Schmidt E**. Pemphigus vulgaris. Internist Prax 2011, 51: 295-308. IF 0.25

(32) **Schmidt E**, Zillikens D. Modern diagnosis of autoimmune blistering diseases. Autoimmun Rev 2010, 10: 84-89. IF 6.6

(33) **Schmidt E**, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010, 302: 241-53. IF 2.0

(34) Bieber K, Sun S, Ishii N, Kasperkiewicz M, **Schmidt E**, Hirose M, Westermann J, Yu X, Zillikens D, Ludwig RJ. Animal models for autoimmune bullous dermatoses. Exp Dermatol 2009, 19:2-11. IF 3.3

(35) Kasperkiewicz M, **Schmidt E**. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009; 6: 270-280. IF 0.25

(36) Ludwig RJ, **Schmidt E**. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009; 144: 339-49. IF 0.25

(37) **Schmidt E**. Optimizing therapy in patients with severe autoimmune blistering skin diseases. Hautarzt 2009; 60: 633-40. IF 0.4

(38) **Schmidt E**, Zillikens D. Diagnosis and clinical severity markers of bullous pemphigoid. F100 Medicine Reports 2009, 1: 15-18. IF 0.3

(39) **Schmidt E**, Waschke J. Apoptosis in pemphigus. Autoimmun Rev 2009, 8: 533-7. IF 6.4

(40) **Schmidt E**, Zillikens D. Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009; 7: 296-300. IF 1.4

(41) **Schmidt E**, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-91. IF 1.7

(42) Meyer-ter-Vehn T, **Schmidt E**, Zillikens D, Geerling G. Therapie des Schleimhautpemphigoid mit okulärer Beteiligung. Ophthalmologe 2008, 105: 405-19. IF 0.8

(43) **Schmidt E**, Meyer-ter-Vehn T, Zillikens D, Geerling G. Klinik, Pathogenese und Diagnostik des Schleimhautpemphigoid mit okulärer Beteiligung. Ophthalmologe 2008, 105: 285-298. IF 0.8

(44) **Schmidt E**, Goebeler M. Use of CD20-directed therapy in autoimmune skin diseases. Exp Rev Dermatol 2008, 3: 259-278. IF 0.3

(45) **Schmidt E**, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008, 34: 56-64. IF 1.7

(46) Benoit S, Bröcker EB, **Schmidt E**. Current treatment of pemphigus. G Ital Dermatol Venereol 2007; 142: 363-380. IF 0.3

(47) **Schmidt E**, Hunzelmann N, Zillikens D, Bröcker E-B, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31:503-08. IF 1.3

(48) Jainta S, **Schmidt E**, Bröcker EB, Zillikens D. Diagnostik und Therapie bullöser Autoimmunerkrankungen der Haut. Dt Ärztebl 2001; 98: A 1320-1325. IF 0.3

(49) **Schmidt E**, Bröcker EB, Zillikens D. Neue Aspekte zur Pathogenese des bullösen Pemphigoid. Hautarzt 2000, 51: 637-645. IF 0.5

(50) **Schmidt E**, Bröcker EB, Zillikens D. Pemphigus: Verlust des desmosomalen Zell-Zell Kontaktes. Hautarzt 2000, 51: 309-318. IF 0.5

(51) **Schmidt E**, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 2000; 16: 113-157. IF 0.3

IF total: 209.8

Book chapters

(1) Van Beek, **Schmidt E**. Autoimmune bullous diseases. In Irvine AD, Hoeger PH, Yan AC (Hrsg). Harper's Texbook of Pediatric Dermatology. 3rd edition. Wiley-Blackwell, in press.

(2) **Schmidt E**, Groves R. Immunobullous diseases. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (Hrsg.). Rook's Textbook of Dermatology. 9th edition. Wiley-Blackwell, 2016, 50.01-50-56.

(3) **Schmidt E**, Zillikens Z. Immunfluoreszenztechniken. In: Kerl H, Garbe C, Cerroni L, Wolff HH (Hrsg.) Histopathologie der Haut. 2. Auflage. Springer, Heidelberg, 2016, 46-59.

(4) Schumacher N, Mook SC, Shimanovich I, Zillikens D, **Schmidt E.** Life-threatening pemphigus vulgaris. In: Murrell D (Hrsg). Clinical cases in autoimmune blistering diseases. Springer, Heidelberg, 2015, 35-43.

(5) **Schmidt E**, Borradori L, Joly P. Epidemiology of autoimmune bullous diseases. In: Murrell D (Hrsg). Blistering diseases. 1st edition. Springer, Heidelberg, 2015, 251-264.

(6) **Schmidt E**, Borradori L, Sprecher E, Marinovic B, Sinha AA, Joly P. Genetic and environmental risk factors of autoimmune bullous diseases. In: Murrell D (Hrsg). Blistering diseases. 1st edition. Springer, Heidelberg, 2015, 131-140.

(7) Hammers C, **Schmidt E**, Borradori L. Pemphigus foliaceus & pemphigus erythematosus. In: Katsambas AD et al. (Hrsg.) European Handbook of Dermatological Treatments. 3rd edition. Springer, Heidelberg, 2015, 691-700.

(8) Hammers C, **Schmidt E**, Borradori L,. Pemphigus vegetans. In: Katsambas AD et al. (Hrsg.) European Handbook of Dermatological Treatments. 3rd edition. Springer, Heidelberg, 2015, 701-705.

(9) Schumacher N, **Schmidt E**. Bullöse Autoimmundermatosen: Pemphigus-Gruppe. In: von Stebut E, Berneburg M, Maurer M, Steinbrink K (Hrsg.) Facharztprüfung Dermatologie und Venerologie: 1000 kommentierte Prüfungsfragen. Thieme, Stuttgart, 2014, 153-59.

(10) **Schmidt E**, Zillikens D. Immunoadsorption treatment for autoimmune bullous diseases. In: (Hrsg.) Braun, N. Fundamentals and applications of immunoadsorption. 2nd edition. UNI-MED, Bremen, 2013, 46-59.

(11) Welzel J, Maier T, Kaatz M, Dissmond J, Körber A, **Schmidt E**. Neue diagnostische und therapeutische Methoden. In: Ruzicka T, Wolff H, Thomas P, Prinz J (Hrsg.) Fortschritte der praktischen Dermatologie und Venerologie 2012. Springer, Heidelberg, 2013, 468-78.

(12) Welzel J, Kaatz M, Hohenleutner U, **Schmidt E**. Neue diagnostische und therapeutische Methoden. In: Ruzicka T, Wolff H, Thomas P, Prinz J (Hrsg.) Fortschritte der praktischen Dermatologie und Venerologie 2010. Springer, Heidelberg, 2011, 403-12.

(13) **Schmidt E**, Zillikens D. Immunoadsorption treatment for autoimmune bullous diseases. In: (Hrsg.) Braun, N. Fundamentals and applications of immunoadsorption. UNI-MED, Bremen, 2009.

(14) **Schmidt E**, Kromminga A, Zillikens D, Zimmermann U. Simple and sensitive detection of serum autoantibodies to full-length bullous pemphigoid antigen 180. In: Conrad K, Fritzler M, Meurer, Sack U, Shoenfeld Y (Hrsg.) From proteomics to molecular epidemiology: releavance of autoantibodies. Pabst, Lengerich, 2002, 71-80.

(15) **Schmidt E**, Obe K, Giudice GJ, Bröcker EB, Zillikens D. Antikörper gegen BP180 korrelieren mit der Krankheitsaktivität des bullösen Pemphigoids. In: Meigel WN, Moll I, Plettenberg A (Hrsg.). Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Heidelberg Berlin 1999, 81-83.